Physician profile
Steven E Saltman
NPI 1770579153
$8,453.88
in general payments reported to CMS, 2019-2025
41 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,195 · 2020: $239 · 2021: $1,685 · 2022: $991 · 2023: $1,399 · 2024: $1,085 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,269 · Gift: $59.40 · Education: $15.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,268.56 |
| Gift | $59.40 |
| Education | $15.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,379.69 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,084.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $840.56 | 2019-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $538.43 | 2021-2025 | Jardiance |
| Abbott Laboratories | $484.83 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $433.53 | 2019-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $382.42 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $360.98 | 2019-2025 | |
| Corcept Therapeutics | $317.75 | 2021-2025 | Korlym |
| Insulet Corporation | $273.81 | 2021-2025 | Omnipod |
| Abbvie INC. | $268.78 | 2019-2025 | Synthroid |
| Novartis Pharmaceuticals Corporation | $208.32 | 2024-2025 | |
| Mannkind Corporation | $200.38 | 2021-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $175.74 | 2022-2025 | |
| Ibsa Pharma INC. | $150.82 | 2025 | Tirosint, Flector, Licart |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $148.60 | 2023-2025 | Isturisa, Signifor Lar |
| Lifescan, INC. | $101.00 | 2019-2021 | |
| Horizon Therapeutics Plc | $93.80 | 2020-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $90.75 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $90.68 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $84.23 | 2025 | |
| Radius Health, INC. | $84.18 | 2019-2024 | Tymlos |
| Tandem Diabetes Care, INC. | $77.60 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $62.49 | 2019-2025 | Strensiq |
| Sequel Med Tech, LLC | $60.82 | 2025 | Twiist |
| Amarin Pharma, INC. | $53.46 | 2019-2021 | |
| Madrigal Pharmaceuticals | $46.20 | 2025 | Rezdiffra |
| Medtronic, INC. | $46.02 | 2021-2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $38.56 | 2019 | |
| Neurocrine Biosciences, INC. | $32.19 | 2025 | |
| Grt US Holding, INC. | $28.92 | 2022 | |
| Cequr Corporation | $24.22 | 2023 | Cequr Simplicity |
| Regeneron Healthcare Solutions, INC. | $23.98 | 2019 | |
| Astellas Pharma US INC | $23.96 | 2024 | Veozah |
| Valeritas, INC. | $23.59 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $21.66 | 2025 | |
| Bigfoot Biomedical INC | $21.45 | 2022 | |
| Antares Pharma, INC. | $20.20 | 2021 | |
| Esperion Therapeutics, INC. | $19.39 | 2021 | |
| Pfizer INC. | $17.57 | 2023 | |
| Beta Bionics, INC. | $17.33 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Saltman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.